Primary adrenal insufficiency in a child after busulfan and cyclophosphamide-based conditioning for hematopoietic stem cell transplantation

J Pediatr Endocrinol Metab. 2011;24(9-10):853-5. doi: 10.1515/jpem.2011.131.

Abstract

High rates of skeletal complications, growth disturbances, thyroid and gonadal dysfunction have been described in children undergoing stem cell transplantation. Although secondary adrenal insufficiency has been diagnosed, no primary adrenal insufficiency has been reported after busulfan and cyclophosphamide (Bu/Cy)-based conditioning regimens for stem cell transplantation in children. A 9-year-old girl with myelodysplastic syndrome was treated with stem cell transplantation of allogeneic origin. She received myeloablative conditioning chemotherapy, Bu and Cy. Her serum cortisol level was normal before stem cell transplantation. Then, 17 months after stem cell transplantation, chronic graft-versus-host disease developed and was treated with methyl prednisolone for 3 months. The control endocrinological investigation revealed low serum cortisol and high serum adrenocorticotropin (ACTH) levels 6 months after completion of methyl prednisolone treatment. The ACTH stimulation test demonstrated primary adrenal insufficiency, and the other etiologies of primary adrenal insufficiency were excluded. The patient received oral prednisolone replacement therapy. She was followed-up for 44 months and required increases in steroid doses during stress periods. Primary adrenal insufficiency which was observed in our patient after Bu/Cy-based conditioning regimen for stem cell transplantation has not been reported in children and adrenal function should be closely monitored in these patients both before stem cell transplantation and after stem cell transplantation.

Publication types

  • Case Reports

MeSH terms

  • Addison Disease / chemically induced*
  • Busulfan / adverse effects*
  • Child
  • Cyclophosphamide / adverse effects*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Myeloablative Agonists / adverse effects
  • Myelodysplastic Syndromes / therapy*
  • Transplantation Conditioning / adverse effects*

Substances

  • Myeloablative Agonists
  • Cyclophosphamide
  • Busulfan